Heparin coagulant super-sensitivity during leech therapy
Case report published in Thrombosis Journal (2026)
Abstract
BACKGROUND: Leech therapy is used in diverse ways in the medical field, such as for flap salvation and for treatment of osteoarthritis. While bleeding is a recognized adverse effect, severe coagulopathy is rare and underreported, especially when compounded by concurrent anticoagulant use. CASE PRESENTATION: We present a case of a 76-year-old female undergoing leech therapy in combination with systemic heparin for free flap salvage following partial glossectomy and neck dissection. Shortly after initiating both therapies, the patient developed marked coagulopathy, evidenced by prolonged activated partial thromboplastin time (aPTT), elevated thrombin time, and persistent bleeding from the surgical site. Laboratory results suggested synergistic anticoagulant effects of heparin and hirudin, the potent direct thrombin inhibitor secreted by medicinal leeches. Despite discontinuation of systemic heparin, bleeding persisted until leech therapy was halted. The patient received 8 units of packed red blood cells (pRBCs) during the treatment course. Coagulation markers normalized after cessation of leech therapy, with no further bleeding events. CONCLUSIONS: This case highlights a potentially underrecognized risk of coagulopathy in patients undergoing combined leech and systemic anticoagulation therapy. The mechanistically distinct pathways of heparin and hirudin may act synergistically to impair both free and clot-bound thrombin activity. Given the absence of formal guidelines for coagulopathy monitoring in such cases, we propose daily assessment of coagulation markers including aPTT, PT/INR, and a one-time measurement of thrombin time and anti-Xa levels after treatment initiation. This report underscores the need for standardized protocols and further research to guide safe implementation of leech therapy, particularly in patients receiving systemic anticoagulation.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Case of unexpected heparin coagulant super-sensitivity in a patient receiving medicinal leech therapy — important safety signal for combined heparin-MLT regimens.
Por qué esto importa para la hirudoterapia
Este caso clínico describe a una mujer de 76 años que desarrolló una coagulopatía marcada—aPTT prolongado, tiempo de trombina elevado y sangrado persistente en el sitio quirúrgico—durante la terapia concurrente con sanguijuelas y heparina sistémica para el rescate de un colgajo libre tras glosectomía parcial, requiriendo 8 unidades de concentrado de eritrocitos antes de su resolución tras la interrupción de la terapia con sanguijuelas. Los hallazgos de laboratorio sugirieron efectos anticoagulantes sinérgicos entre la heparina y la hirudina a través de vías mecanísticamente distintas. Esto es directamente relevante para el ámbito de la ASH, al destacar una consideración crítica de seguridad en hirudoterapia: el potencial de una coagulopatía exagerada cuando la aplicación de sanguijuelas medicinales se combina con anticoagulación sistémica. Los autores proponen protocolos de monitorización que incluyen aPTT diario, PT/INR y una medición única de tiempo de trombina y anti-Xa. Sin embargo, se trata de un caso clínico único, y las recomendaciones de monitorización propuestas no se derivan de estudios controlados, guías formales ni evidencia sistemática.
Citación
Heparin coagulant super-sensitivity during leech therapy.
Rong Z et al. · Thrombosis journal, 2026
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026